Insmed puts further Iplex trials on hold and limits ALS use
This article was originally published in Scrip
Executive Summary
Insmed will not initiate further clinical trials with its lead candidate, Iplex (mecasermin rinfabate [rDNA origin]), at this time. The product is a recombinant complex of insulin-like growth factor-1 and its binding protein (IGFBP3). Insmed stated that it will be "considering its development options".